Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
135 participants
OBSERVATIONAL
2018-12-19
2024-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this project is to update the current EORTC QLQ-BN20 questionnaire.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An unpublished systematic review conducted by our group revealed that since the publication of the QLQ-BN20 in 1996, there has been an increase in the use of this questionnaire, not only in glioma patients for whom this questionnaire was developed, but also in meningioma patients, patients with brain metastases or groups with mixed types of brain tumors. The use of the QLQ-BN20 showed an increase over time: from 20 publications in the period 1996-2006, to 98 publications in the period 2007-2016.
One of the reasons for updating the current QLQ-BN20 questionnaire is that were have encountered limitations in the use of specific items. For example, the item referring to the occurrence of seizures results in an underestimation of the true prevalence of seizures. In previous clinical studies it was shown that 30-60% of the brain tumor patients experience seizures. In contrast, large randomized controlled trials using the QLQ-BN20 to determine seizure occurrence showed prevalences of only 6 to 14 percent. This is probably due to the time frame that is used for this item, i.e. the 'last week'. Although seizures are frequent, they often do not occur weekly. With the current response format, detection of seizures is difficult and this should be taken into account in the revision of the QLQ-BN20 questionnaire. Second, several items show severe floor-effects. Probably the most important reason to revise the current QLQ-BN20 questionnaire is because major advances in the treatment of brain tumors have been made in the last 20 years. Compared to 20 years ago, when the QLQ-BN20 was developed, current standard treatment (multimodal treatment including surgery, radiotherapy and chemotherapy) is different and treatments have a different toxicity profile. Moreover, new treatment opportunities are currently explored and include targeted treatment and immunotherapy. These types of treatment bring new toxicities, e.g. eye, skin and endocrine function problems. The current brain tumor module lacks sufficient coverage of domains that are affected by current and new treatment options.
Thus, despite the fact that use of the QLQ-BN20 has tremendously contributed to insight into the quality of life of brain tumor patients, several observations have led to the recognition that a revision of the QLQ-BN20 is warranted. Therefore, the aim of this project is to update the current EORTC QLQ-BN20 questionnaire.
Aim: The overall aim of this study is to update the current EORTC QLQ-BN20 questionnaire for use in brain tumor patients.
Study design: The methods for this prospective study will follow the EORTC Quality of Life Group guidelines for updating existing modules, including a literature review, interviews with patients and health care professionals (for the identification of items relevant to current/new treatments (phase I)), creation of a revised item list (phase II), and psychometric pilot testing (phase III).
Phase 1: Semi-structured interviews with 27 patients and 6 healthcare professionals to identify relevant issues for brain tumor patients (these issues are identified with a systematic literature review and have to reflect the patients' functioning and well-being, such as symptoms / impairments, activities in daily life and participation restrictions).
Phase 2: Construction of a comprehensive item list with items that are relevant for brain tumor patients (including construction of items, and translations).
Phase 3: The draft item list resulting from phase II will be pretested in 108 patients from at least 6 countries in 4 main European regions and Asia (Netherlands, Germany, Italy, United Kingdom, Switzerland, Croatia, Jordan and Japan). The primary aim of pretesting the module is to identify and solve potential problems (phrasing, sequence questions) and to identify missing or redundant items. Second, preliminary psychometric testing will be performed.
The questionnaire resulting from phase III will subsequently be field-tested in a large, international group of patients in order to determine its acceptability, reliability, validity, responsiveness and cross-cultural applicability. This is currently not part of the study protocol, but will commence after phase III is successfully completed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1
Patients recruited for phase 1 will undergo a semi-structured interview to identify issues that may be relevant to include in the revised EORTC QLQ-BN20 questionnaire.
No intervention
This is not an interventional study.
Phase 3
Patients recruited for phase 3 will complete the draft questionnaire, and rate each item for relevance, and indicate the 10 most important items. Also, a semi-structured interview will be conducted including debriefing questions to determine if the questionnaire is complete and the questions are acceptable.
No intervention
This is not an interventional study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
This is not an interventional study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients: ≥18 years of age
* Willing to provide written informed consent
Exclusion Criteria
* Patients with any psychiatric condition or cognitive impairment, as determined by the treating physician, that would hamper undergoing semi-structured interviews.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Center Haaglanden
OTHER
Regina Elena Cancer Institute
OTHER
San Giovanni Addolorata Hospital
OTHER
NHS Lothian
OTHER_GOV
University Hospital Regensburg
OTHER
University Hospital, Bonn
OTHER
University of Zurich
OTHER
National Cancer Center, Japan
OTHER_GOV
King Hussein Cancer Center
OTHER
Clinical Hospital Center Rijeka
OTHER
Leeds Cancer Centre at St. James's University Hospital
OTHER
Leiden University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
LindaDirven
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda Dirven, PhD
Role: PRINCIPAL_INVESTIGATOR
Leiden University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leiden University Medical Center
Leiden, South Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Martin Taphoorn, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P18.095
Identifier Type: -
Identifier Source: org_study_id